Find Clinical Trials

Inclusion Criteria: * Patient who receive breast reconstruction * Patient who is willing to fill in the questionnaire Exclusion Criteria: * Patient who receive breast reconstruction for the reason other than breast cancer

Inclusion Criteria: * Subjects from all ethnic backgrounds will be eligible to participate. * Having clinically significant depressive symptoms based on a score \>40 on the Children's Depression Rating Scale-Revised * Prescribed more than 5mg of Fluoxetine (Prozac) * Has an identifiable legal guardian. Exclusion Criteria: * Has been taking a standing psychotropic medication in the past 6 months * Has been taking antibiotics or metformin during the past 6 months (known strong effects on gut microbiome) * Admitted to RCHSD CAPS post-overdose (potential strong effects on gut microbiome) * Currently using nicotine-containing substances (known strong effects on gut microbiome)

Inclusion Criteria: 1. Male and non-pregnant, non-lactating female subjects aged between 18 to 65 years (both ages inclusive) 2. Stable mild asthmatics based on National Asthma Education and Prevention Programme (NAEPP) guidelines 3. Subjects who were diagnosed by physician with mild asthma at least 6 months prior to screening visit date 4. Pre-bronchodilator forced expiratory volume in one second (FEV1) ≥ 80% of predicted 5. Airway responsiveness to methacholine demonstrated by pre-albuterol-dose (baseline) PC20 less than or equal to 1.56 mg/mL using AeroEclipse II BAN and 1-minute tidal breathing method at Screening MCT A 6. The ≥20% reduction in FEV1 at Screening MCT A relative to post-saline FEV1 should be obtained above the lowest methacholine concentration 7. At Screening MCT-B, subjects should have at least four-fold increase in PC20 over Screening MCT-A 8. At Screening MCT -B, the ≥ 20% reduction in FEV1 relative to post saline FEV1 must be obtained up to methacholine concentration 24.96 mg/mL 9. Non-smokers for at least six months prior to screening visit and a maximum smoking history of five-pack years (the equivalent of one pack per day for five years) 10. Women of child-bearing potential or women who are less than or equal to 1 year postmenopausal prior to screening visit must have negative result for urine pregnancy test 11. Women of child-bearing potential or women who are less than or equal to 1 year postmenopausal prior to screening visit must agree to the use of a reliable and medically acceptable method of contraception throughout the duration of the study 12. Women of child-bearing potential or women who are less than or equal to 1 year postmenopausal prior to screening visit using hormonal contraception must be on the same hormonal contraceptive for at least thirty days before the screening period and must be continued same throughout the study. 13. Able to provide signed written informed consent and willing to comply with all aspects of the clinical study protocol Exclusion Criteria: * 1.Subjects with FEV1 \< 1.5L during methacholine challenge test 2.Evidence of upper or lower respiratory tract infection (e.g., pneumonia, bronchitis, sinusitis) within six weeks prior to the study. 3.History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season 4.History of cystic fibrosis, bronchiectasis or other respiratory diseases other than asthma (e.g., COPD, interstitial lung disease) 5.Treatment in an emergency room or hospitalization for acute asthmatic symptoms within past three months prior to screening visit 6.Need for daily oral corticosteroids within past three months prior to screening visit 7.History of life-threatening asthma leading to hospitalization within the past 1 year prior to screening visit 8.Known intolerance or hypersensitivity to any component of the albuterol metered dose inhaler (MDI) 9.Uncontrolled hypertension (systolic BP \>200 mmHg, or diastolic BP \>100 mmHg) 10.History or evidence of myocardial infarction or stroke 11.History of known aortic aneurysm 12.Current use of cholinesterase inhibitor medication (for myasthenia gravis) 13.Clinically significant ECG recording at screening such as flattening of T wave, prolongation of QTc interval (\>450 milliseconds), and ST segment depression, which in the opinion of the Investigator, would compromise subject's safety or interfere with the study results 14.History of recent eye surgery or intracranial pressure elevation risk 15.Uncontrolled diabetes (HbA1c ≥9%) at screening 16.Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled artery disease, cardiac dysrhythmia, or ECG with evidence of ischemic heart disease. In addition, historical or current evidence of significant hematologic, hepatic neurologic, psychiatric, renal, or other disease or that, in the opinion of the Investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbates in the study 17.Presence of any abnormal clinically significant laboratory investigation at screening visit 18.History of paradoxical bronchospasm 19.Has participated in another investigational study or device research study within 30 days before screening visit date 20.Women are pregnant, breast-feeding, or planning pregnancy during study Period continuation criteria If subject does not meet any one Period continuation criteria at any visit of Period; retest visit will be conducted and study treatment dosing should not be administered. Period continuation criteria will be checked for maximum three visits. If subject does not meet all Period continuation criteria at any one visit and within three consecutive visits: At Period 1: subject should not be randomized and will be considered a 'randomization failure' At Period 2 to Period 4: subject should not administer study treatment dosing and must be discontinued from the study 1. Baseline FEV1 should not be less than 70% of predicted normal value and should be within 88 -112% of qualifying day FEV1 value. Baseline FEV1: highest pre-saline FEV1 obtained prior to saline control test at Period MCT and which has met the acceptability criteria and have repeatable quality grade A, B, C mentioned in ATS 2019 standards Qualifying day FEV1 value: highest pre-saline FEV1 obtained prior to saline control test on qualifying day and which has met the acceptability criteria and have repeatable quality grade A, B, C mentioned in ATS 2019 standards and which has not met the retest criteria for Scr-MCT A on qualifying day -Qualifying day: Scr-MCT A PC20 is obtained and the results of the Scr-MCT A on this day confirms that subject has met inclusion criteria 4, 5, and 6 2. Baseline FEV1 should be ≥ 1.5 L 3. Baseline FEV1 should meet FEV1 acceptability criteria as mentioned in ATS 2019 standards 4. Baseline FEV1 should meet repeatability quality grade A, B, or C as mentioned in ATS 2019 standards 5. Fall in FEV1 due to the saline control (i.e. post-saline FEV1) should not be more than 10% from the baseline FEV1 Post-saline FEV1: is the highest post-saline FEV1 value from at least one acceptable FEV1 maneuver obtained after nebulization with normal saline is completed (i.e. after saline control test is completed) 6. At least one FEV1 obtained after saline control test (post-saline FEV1) should meet acceptability criteria mentioned in ATS 2019 standards

Inclusion Criteria: 1. Female patients aged ≤ 80 years old. 2. ECOG score 0-1 points; 3. Breast cancer meets the following criteria: histologically diagnosed as invasive breast cancer, known ER, PR, HER2, KI67 status, pathologically diagnosed as ipsilateral supraclavicular lymph node metastasis (both cytology and histopathology); 4. Estimated patient survival time exceeding three months; 5. No obvious contraindications for surgery or radiotherapy; 6. The researcher judged that they were able to comply with the research protocol. 7. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers not to affect the research protocol can be enrolled normally. 8. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer; 2. Bilateral breast cancer; 3. Received radiotherapy and surgical treatment (excluding local puncture) for ipsilateral supraclavicular metastatic lymph nodes before enrollment; 4. History of breast cancer or other malignant tumors, but excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma; 5. Individuals with severe primary diseases such as cardiovascular, cerebrovascular, liver, and kidney that are difficult to tolerate surgery or radiation therapy; 6. Having a history of immunodeficiency, including HIV testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation; 7. Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study.

Inclusion Criteria: * Biologically female and between the ages of 18-45 years (45 set as upper limit to avoid endocrine changes associated with perimenopause). * Self-reported regular menstrual cycles between 25 and 35 days. * A previous diagnosis of major depressive disorder, with self-reported premenstrual worsening of symptoms. * If the woman has children, she must be at least 1 year postpartum. * English-speaking Exclusion Criteria: * Pregnant, breastfeeding, or trying to become pregnant. Pregnancy status will be confirmed using a urine pregnancy test at the enrollment visit and again at the first visit of the second condition. Women will be instructed to use a barrier method of birth control during the study. * Taking any form of exogenous hormones or IUD, and must have ended previous use of hormonal preparations at least one month prior to the study. Women who were previously taking oral contraceptives or other hormonal medications must have one normal menstrual cycle (menstrual period) prior to enrollment in the study. * BMI less than 18 or greater than 29. * A personal history of any chronic medical condition that could confound the experimental protocol, including but not limited to metabolic or autoimmune disease, epilepsy, endometriosis, cancer, diabetes, cardiovascular, gastrointestinal, hepatic, renal, pulmonary disease, migraine with aura, hypertension, Parkinson's disease, chronic pain, and thromboembolic events. * A family history indicative of increased risk of breast cancer or thromboembolic disorders. * Current cigarette smoking. * A history of mania, psychosis, or substance use disorder. * Any recent history (last 12 months) of active suicidal ideation, or suicide attempt within the last 5 years.

Inclusion Criteria: * Women over 18 years of age living in the Region of Galicia (Spain) * Pregnant with a gestational age ≤ 16 * Understand and speak Spanish fluently * Informed consent to participate in the study * Accessibility to the internet and a digital device ( computer, tablet or smartphone) Exclusion Criteria: * High-risk pregnancy or twins * Being pharmacological treatment for anxiety and/or depression * Not giving their consent

Inclusion Criteria: * Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater * Pregnant with viable fetus at 6 to less than 23 weeks gestation * Maternal age 18-50 years old Exclusion Criteria: * Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions * Multiple gestation * Major fetal anomaly or two or more minor fetal anomalies * Planned delivery outside study consortium * Participating in another conflicting interventional study * Participation in this trial in a previous pregnancy * Patient unable to consent * Physician refusal for other reasons

Inclusion Criteria: * Fluent in English * The primary mental health concern participants want to work on must be that they would like to improve their mood, to reduce negative thoughts, to enjoy more activities again and/or to reduce symptoms of depression * Having a picture ID and be willing to meet with us on a video zoom call for identity verification if invited to do so Exclusion Criteria: * Lack of attention when completing parts of the study, lack of honesty or not completing parts of the study in a timely way * Identity check failure

Inclusion Criteria: * Outpatient persons capable of providing informed consent * Minimum age of 60 years old * MINI International Neuropsychiatric Interview diagnosis of major depressive disorder, based on DSM-5 criteria * MADRS score of ≥15 (moderate/severe depression) * On stable doses of psychotropic medication, including antidepressant medication, for at least 4 weeks * Able to adhere to the intervention schedule Exclusion Criteria: * Current diagnosis of major neurocognitive disorder * Current active psychosis * Unstable medical illness, including clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease * Diagnosis of narrow angle glaucoma * Suspicious, undiagnosed skin lesions or a history of melanoma * History of myocardial infarction * Atrial, nodal, or ventricular arrhythmias * History of seizures or seizure disorder * History of peptic ulcer disease * History of allergy or other hypersensitivity to levodopa, carbidopa, or to any other ingredient in the formulation of Levocarb * Active suicidal ideation * Psychotropic medication initiation or dose change \<4 weeks prior to enrolment * Regular use of dopamine antagonist or benzodiazepines ≥2mg lorazepam equivalent per day * Unable to complete neuropsychological testing in the English language * Have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests) * History of falls, with ≥1 fall per week during the past 4 weeks

Inclusion Criteria: * female * not over the age of 75 years * operated because of stage 1-2 invasive adenocarcinoma of the breast * radical excision of the tumour Exclusion Criteria: * earlier cancer except cancer in situ of the cervix or skin * distant metastases

Inclusion Criteria: * Being over 18 years of age, * Having the ability to read, write, and speak Turkish, * Having a diagnosis of breast cancer, * Having completed surgical treatment, * Having completed chemotherapy or radiation therapy, * Recently starting endocrine therapy, * Having a Body Mass Index (BMI) below 35. Exclusion Criteria: * Being over 70 years of age, * Having a diagnosis of metastatic disease, * Previous participation in yoga or similar exercises, * Having a physical disability that prevents practicing yoga, * Having a condition that causes shortness of breath (e.g., COPD), * Having another chronic heart or lung disease that prevents yoga practice, * Having a serious psychiatric illness or cognitive impairment.

Inclusion Criteria: * Written informed consent obtained before any trial-related procedures are performed * Diabetes, one of the following groups: Type 1 diabetes OR Type 2 diabetes receiving glucose-lowering therapy OR Type 2 diabetes managed with lifestyle changes with an HbA1c ≥ 50 mmol/mol * Maintenance haemodialysis or peritoneal dialysis (minimum of two weeks) * Subject must be willing and able to comply with trial protocol and be fluent in Danish or English Exclusion Criteria: * Major allergy to tape/adhesives * Women who are pregnant or planning pregnancy * Ongoing use of CGM * Ongoing use of insulin pump

Inclusion Criteria: * Patients aged 18 to 75 years and confirmed diagnosis of Platinum-Related Porto-Sinusoidal Vascular Disease or Cirrhosis Due to Hepatitis B * Acute esophagogastric variceal bleeding or history of gastroesophageal variceal bleeding episodes * The patients was received endoscopic variceal ligation/histoacryl injection therapy or TIPS treatment * At least one postoperative follow-up data Exclusion Criteria: * Primary tumor recurrence and metastasis * Hepatocellular carcinoma or other malignant tumors * Common contraindications of TIPS * HIV, AIDS, Serious acute and chronic disease * Pregnant or breast-feeding woman * Without postoperative follow-up data

Inclusion Criteria: * Individuals aged 15 to 59 years. * Patients diagnosed with mood disorders (e.g., bipolar disorder, major depressive disorder) through screening and clinician interviews, according to DSM-5. * Patients with accompanying anxiety symptoms. * Patients with stress symptoms (Perceived Stress Scale score ≥ 10) * Individuals able to independently complete questionnaires and communicate in Korean. * Individuals who voluntarily agree to participate in weekly treatment sessions. Exclusion Criteria: * Patients diagnosed with major psychiatric disorders other than mood disorders (e.g., schizophrenia, substance use disorders including alcohol, obsessive-compulsive disorder). * Patients diagnosed with bipolar disorder who are currently experiencing acute psychotic symptoms or are in a manic state. * Individuals with acute suicidal ideation. * Individuals with co-occurring personality disorders (e.g., borderline personality disorder, antisocial personality disorder, narcissistic personality disorder). * Individuals who have participated in mindfulness-based cognitive therapy within the last 3 months. * Individuals currently receiving other non-pharmacological treatments (e.g., cognitive-behavioral therapy, psychoanalysis). * Individuals with neurological damage or conditions that may cause brain injury (e.g., seizure disorder, cerebrovascular or neoplastic lesion, neurodegenerative disorder, significant head trauma with loss of consciousness lasting more than 5 minutes). * Individuals diagnosed with cardiovascular diseases (e.g., hypertension, coronary artery disease, arrhythmia). * Individuals with hearing impairment or tinnitus. * Individuals with impaired ability to understand the study's purpose or make decisions about participation (e.g., IQ \&lt; 70, dementia). * Individuals with medical, psychological, social, or legal issues that would interfere with continued participation in the program.

Inclusion Criteria for the patients with type 2 diabetes: Diabetes type II diagnose with one of the following: * Duration over 5 years * Moderate microalbuminuria * Non-proliferative diabetic retinopathy * Speaks and understands Danish (required for reliable cognitive testing) * Able to provide informed and written consent Exclusion Criteria or the patients with type 2 diabetes: Moderate to high intensity training \&gt;1 times/week. * Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \&lt;45%), asthma. * Previous stroke or significant neurological disease including cognitive dysfunction. * Ongoing depression. * Hypothyroidism * Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease. Inclusion Criteria for the healthy age-matched controls: * Age \&gt; 60 years * No diagnosis of T2D according to WHO\&#39;s criteria. * Speaks and understands Danish (required for reliable cognitive testing) * Able to provide informed and written consent Exclusion Criteria for the healthy age-matched controls: * Moderate to high intensity training \&gt;2 times/week. * Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \&lt;45%), asthma. * Previous stroke or significant neurological disease including cognitive dysfunction. * Ongoing depression. * Hypothyroidism * Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

Inclusion Criteria: * 19-35 years old * caesarean section * primiparous * breastfeeding women Exclusion Criteria: * women who refused to participate in the research.

Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and followup, and documented according to the local regulatory requirements. 2. Postmenopausal women with age at diagnosis ≥ 18 years. Postmenopausal status is defined as: * Age ≥60 years * Age \<60 years and amenorrhea for at least 12 continuous months with no identified cause other than menopause * Bilateral oophorectomy Negative pregnancy test (urine or serum) within 14 days prior to randomization for all postmenopausal women 50 years of age or younger without bilateral oophorectomy 3. Unilateral or bilateral primary untreated lobular invasive carcinoma of the breast. In case of bilateral breast cancer, both sides must be lobular; the lead tumor has to be defined by the investigator based on the inclusion criteria for the respective subtype and the risk status. Lobular histology has to be centrally confirmed. 4. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE) tissue block from core biopsy before the start of neoadjuvant therapy. 5. Centrally confirmed HER2-negative (IHC score 0-1+ or ISH negative according to ASCO/CAP guideline) and HR-positive (≥10% positive stained cells) disease, assessed on the core of diagnostic biopsy. Ki67% \>10% is required. In case of bilateral breast cancer, HER2-negative, HR-positive and lobular histology status has to be confirmed for both sides. 6. Patients with invasive lobular breast cancer at high risk for recurrence defined as cT1c and clinical nodal involvement (cN+) or ≥ cT2 disease (irrespective of nodal involvement). 7. No clinical evidence of distant metastases. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. 9. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer. 10. The patient must be accessible for scheduled visits, treatment, and followup. 11. Normal cardiac function must be confirmed according to local guidelines. 12. Laboratory requirements: Hematology * Absolute neutrophil count (ANC) ≥1.5 x 109 / L * Platelets ≥100 x 109 / L * Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function * Total bilirubin \<1.25x ULN * AST and ALT \<=1.5x ULN * Alkaline phosphatase \<=2.5x ULN Glucose Metabolism * HbA1c \<8.0% (63.9 mmol/mol) Renal Function * Creatinine \<1.25x ULN or creatinine clearance ≥50 ml/min (if creatinine is above ULN according to Cockroft-Gault) 13. Complete staging work-up prior to the initiation of neoadjuvant therapy as per standard recommendations. Exclusion Criteria: 1. Female patients of childbearing potential. 2. Excisional biopsy or lumpectomy performed prior to study entry. 3. Surgical axillary staging procedure including sentinel lymph node biopsy prior to randomization. Exceptions: FNA or core biopsy of an axillary lymph node. 4. Any previous treatment including endocrine therapy, chemotherapy, radiotherapy or targeted therapy (including AKT inhibitor or PIK3 inhibitor) for the currently diagnosed breast cancer. 5. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer. 6. Known hypersensitivity reaction to one of the compounds or substances used in this protocol. 7. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort). 8. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib. 9. Any contraindication for fulvestrant. 10. Patients with definitive clinical or radiologic evidence of stage IV cancer (metastatic disease) are not eligible. 11. Patients with a history of any malignancy are ineligible with the following exceptions: * Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy except for breast cancer. * CIS of the cervix, basal cell and squamous cell carcinomas of the skin. 12. History of type I or type II diabetes mellitus requiring insulin. 13. Severe and relevant co-morbidity that would interact with the application of study drugs or the participation in the study, including cerebrovascular incident including transient ischemic attack, or symptomatic pulmonary embolism, active infection requiring intravenous anti-microbial treatment (antibiotics, anti-fungal, and anti-viral drugs) within 1 week of enrolment. Patients with confirmed Gilbert's syndrome may be included in the study. 14. Known medically history of HIV infection, tuberculosis, or hepatitis B. 15. History of and/or active cardiac disease that would preclude the use of study treatments. This includes but is not confined to any of the following cardiac criteria: * Clinically significant cardiac dysfunction including heart failure (NYHA II-IV), active ventricular arrhythmias requiring medication or arrhythmias requiring a pacemaker, and history of a myocardial infarction within 6 months prior to randomization, angina pectoris, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, angioplasty, or vascular stent. * Mean resting QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from 3 consecutive ECGs. * Increased risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled electrolyte disorders (e.g., hypocalcemia, hypokalemia, or hypomagnesemia), potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval. 16. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving therapy. 17. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent. 18. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension or hypotension (BP \<50mmHg), significant aneurysm, renal transplant and active bleeding diseases). 19. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. 20. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

Inclusion criteria: * WHO performance scale ≤ 2 * Females at least 50 years of age with an ipsilateral invasive breast cancer event or DCIS (i.e. recurrence, second primary) after previous breast conserving surgery and radiotherapy (for invasive breast cancer/carcinoma in situ) * Tumor characteristics: - - Tumor size ≤ 2 cm, unifocal on MRI On tumor biopsy: * Bloom-Richardson grade 1 or 2, * non-lobular invasive histological type carcinoma, * accompanying (non-extensive) DCIS is accepted within the tumor size of 2 cm on mammography and/or tumor biopsy, including no non-mass enhancement on MRI, * ER-positive and HER2-negative tumor, * No lymphovascular invasion. * Clinical node negative on PET-CT, ultrasound and MRI * No distant metastases * Repeat breast-conserving surgery is feasible, if no or mild late toxicity (no grade 2 or higher) from previous breast-conserving therapy * Adequate communication and understanding skills of the Dutch language * Written informed consent Exclusion criteria: * Ipsilateral invasive breast cancer recurrence less than 2 years after first breast conserving therapy for breast cancer or ductal carcinoma in situ * Legal incapacity * Known breast cancer mutation gene carrier * Previous ipsilateral mastectomy * Collagen synthesis disease (e.g. Osteogeneis imperfecta, Ehlers-Danlos syndrome, systemic lupus erythematosus) * Invasive lobular carcinoma * MRI absolute contraindications as defined by the Department of Radiology * Indication for treatment with neoadjuvant chemotherapy * Non-feasible dosimetric RT plan * Breast implants

Inclusion Criteria: * Age \> 60 years * English or Spanish speaking * Self-report or physician diagnosis of asthma \>1 year ago * Uncontrolled asthma Exclusion Criteria: * Dementia * Chronic obstructive pulmonary disease (COPD), or other chronic respiratory illnesses, * Congestive Heart Failure (CHF, New York Heart Association \[NYHA\] stages 4-5) * Cigarette smoking \>15 packs-years

Inclusion Criteria: 1. Ability to confirm voluntary participation and agree to all purposes of the study, signing and dating the Informed Consent Form in two copies. 2. Age ≥ 18 years. 3. Medical office blood pressure with SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg without pharmacological treatment or which is not adequately controlled with monotherapy or with a combination of two drugs in which at least one of the drugs is not at the maximum dose. 4. Uncontrolled arterial hypertension (medical office BP with SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) after at least two (02) weeks of run-in treatment. 5. Compliance with run-in treatment ≥ 80% and ≤ 120%. Exclusion Criteria: 1. Pregnant or lactating women. 2. Women in the reproductive age or of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or expressly declare themselves to be free from the risk of pregnancy because they do not engage in sexual practices or engage in them in a non-reproductive manner. 3. Medical office blood pressure with SBP ≥ 180 mm Hg or DBP ≥ 110 mm mmHg. 4. Resistant hypertension or secondary hypertension of any etiology (including renovascular disease, pheochromocytoma and Cushing\&#39;s syndrome). 5. Concomitant presence of Coronary Artery Disease, Congestive Heart Failure, Liver Failure and/or Chronic Kidney Disease stage IV or V. 6. History of hypertensive emergencies in the last 6 months. 7. Moderate to severe cardiovascular (acute myocardial infarction or unstable angina, unstable or life-threatening arrhythmia) and/or cerebrovascular events within the last 6 months or any other disorder that in the opinion of the investigator excludes the participant from the study. 8. Participant who is unwilling to switch from hypertension treatment to study medications. 9. 12-lead electrocardiogram (ECG) with any clinically significant abnormality. 10. Drug or alcohol abuse in the last 2 years. 11. Allergic or hypersensitivity reactions to angiotensin II receptor blockers, thiazide diuretics or medication excipients.